Scarica l'app Stockscreener
0.8048
0.73%
0.0058
Dopo l'orario di chiusura:
.79
-0.0148
-1.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$0.799
Aprire:
$0.8
Volume 24 ore:
60,816
Relative Volume:
0.41
Capitalizzazione di mercato:
$22.54M
Reddito:
-
Utile/perdita netta:
$-58.52M
Rapporto P/E:
-0.3851
EPS:
-2.09
Flusso di cassa netto:
$-45.03M
1 W Prestazione:
-2.21%
1M Prestazione:
+4.38%
6M Prestazione:
-50.32%
1 anno Prestazione:
-34.03%
Intervallo 1D:
$0.7801
$0.815
Intervallo di 1 settimana:
$0.771
$0.848
Portata 52W:
$0.76
$2.57
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Confronta NXTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.8048 | 22.54M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-03-05 | Aggiornamento | Truist | Hold → Buy |
| 2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Downgrade | SunTrust | Buy → Hold |
| 2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-03-24 | Iniziato | The Benchmark Company | Buy |
| 2020-03-02 | Iniziato | ROTH Capital | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-05 | Iniziato | Needham | Buy |
| 2019-11-26 | Iniziato | BTIG Research | Buy |
| 2019-07-09 | Iniziato | BofA/Merrill | Buy |
| 2019-06-03 | Iniziato | Morgan Stanley | Overweight |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times
NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India
The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World
FDA clears IND for B7-H4-targeting ADC - BioWorld Online
NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com
NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan
NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa
NextCure Advances with New Cancer Drug Application - TipRanks
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
NextCure's NC605 Shows 90% Fracture Prevention in Breakthrough Bone Disease Study | NXTC Stock News - StockTitan
Logos Global Management LP Reduces Stake in NextCure Inc - GuruFocus.com
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation - Simply Wall St
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
National Presto Industries, Inc. (NYSE:NPK) Shares Sold by State of Alaska Department of Revenue - Defense World
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clin - WICZ
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
Intuitive Surg Inc (ISRG-Q) QuotePress Release - The Globe and Mail
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Elevation Capital Advisory LLC Purchases New Shares in Vanguard Information Technology ETF (NYSEARCA:VGT) - americanbankingnews.com
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP - Defense World
Next plc Executes Share Buyback Program - TipRanks
Nexteq PLC Announces Share Buyback and Voting Rights Update - TipRanks
Next PLC Executes Share Buy-Back for Cancellation - TipRanks
Next plc Conducts Share Buyback and Cancellation - TipRanks
Next lifts profit guidance to almost £1bn - Investors Chronicle
Next PLC’s Fresh Guidance Lift, Overseas Plans Boost Shares - The Wall Street Journal
Next PLC Impresses Investors with Yet Another Guidance Upgrade - TipRanks
Next is approaching a historic profit landmark- what is driving this growth? - Proactive Investors Australia
Next Shares Rise 3% As Full-Year Estimates Hiked - Forbes
Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com South Africa
Record high for Next shares after guidance raised again - Interactive Investor
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):